Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17045209 | 1.00 | TAAR1 (0.44) | TAAR1CYP1A2CYP2A6AGXTIDO1 | |
| SCHEMBL11068499 | 0.80 | SLC6A4 (0.58) | TAAR1CYP1A2CYP2A6AGXTIDO1 | |
| SCHEMBL24017125 | 0.80 | TAAR1 (0.48) | TAAR1CYP1A2CYP2A6AGXTIDO1 | |
| SCHEMBL24017123 | 0.80 | TAAR1 (0.48) | TAAR1CYP1A2CYP2A6AGXTIDO1 | |
| SCHEMBL22013359 | 0.80 | TAAR1 (0.48) | TAAR1CYP1A2CYP2A6AGXTIDO1 | |
| SCHEMBL42179 | 0.78 | TAAR1 (0.64) | TAAR1CYP2A6SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL22873938 | 0.78 | TAAR1 (0.64) | TAAR1CYP2A6SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10918313 | 0.78 | IDO1 (0.44) | TAAR1CYP1A2CYP2A6AGXTIDO1 | |
| SCHEMBL81938 | 0.78 | TAAR1 (0.64) | TAAR1CYP2A6SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL14040458 | 0.76 | IDO1 (0.48) | TAAR1CYP1A2CYP2A6AGXTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-07-13 | — | — | US | claimed |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS., LTD. | 2021-04-22 | — | — | US | claimed |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-01-12 | — | — | US | claimed |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2020-02-13 | — | — | US | claimed |
| US-9833432-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-12-05 | — | — | US | claimed |
| EP-3110792-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK Biopharmaceuticals Co., Ltd. (KR) | 2017-01-04 | — | — | EP | claimed |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. | 2016-10-20 | — | — | US | claimed |
| US-9403761-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-08-02 | — | — | US | claimed |
| WO-2015130121-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | WO | claimed |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | US | claimed |
| EP-4395763-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME THERAPEUTICS (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| WO-2023034944-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME THERAPEUTICS (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS., LTD. | 2021-04-22 | — | — | US | disclosed |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-01-12 | — | — | US | disclosed |
| EP-3110792-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK Biopharmaceuticals Co., Ltd. (KR) | 2017-01-04 | — | — | EP | disclosed |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. | 2016-10-20 | — | — | US | disclosed |
| US-9403761-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-08-02 | — | — | US | disclosed |
| WO-2015130121-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | WO | disclosed |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | TAAR1 79/4885CYP1A2 1175/4885CYP2A6 694/4885 |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SLC6A3, SLC6A2, SLC6A4 | TAAR1 79/4885CYP1A2 1175/4885CYP2A6 694/4885 |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | TAAR1 79/4885CYP1A2 1175/4885CYP2A6 694/4885 |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | TAAR1 79/4885CYP1A2 1175/4885CYP2A6 694/4885 |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | TAAR1 79/4885CYP1A2 1175/4885CYP2A6 694/4885 |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | TAAR1 79/4885CYP1A2 1175/4885CYP2A6 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.